| Co-Investigator(Kenkyū-buntansha) |
KUSUHARA Hiroyuki 東京大学, 大学院・薬学系研究科, 准教授 (00302612)
MAEDA Kazuya 東京大学, 大学院・薬学系研究科, 助教 (00345258)
HAYASHI Hisamitsu 東京大学, 大学院・薬学系研究科, 助教 (10451858)
KUMAGAI Yuji 北里大学, 医学部, 准教授 (40215017)
SUWA Toshio 慶應義塾大学, 薬学部, 教授 (20383664)
|
|---|
| Budget Amount *help |
¥46,410,000 (Direct Cost: ¥35,700,000、Indirect Cost: ¥10,710,000)
Fiscal Year 2011: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2010: ¥14,690,000 (Direct Cost: ¥11,300,000、Indirect Cost: ¥3,390,000)
Fiscal Year 2009: ¥14,690,000 (Direct Cost: ¥11,300,000、Indirect Cost: ¥3,390,000)
Fiscal Year 2008: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Research Abstract |
We demonstrated several in vitro assays and validated human clinical studies for the search of probe substrate and inhibitor drugs for drug transporters which can be used in vivo in humans. As a result of our investigation, we found good probe substrate and inhibitor drugs for OAT1, OAT3 and OCT2(renal uptake transporters), MATEs(renal efflux transporter), OATPs(hepatic uptake transporters) and MRP2(biliary excretion transporter).
|
